Are peptides safe after breast cancer or with a hormone-sensitive cancer history?

The short answer

Evidence tier: 3 — observational and genetic data on IGF-1, RCT meta-analyses for GLP-1 cancer incidence, and no human data at all for BPC-157, TB-500 or kisspeptin in cancer survivors.

No peptide has been shown to be safe after breast cancer, and none has been shown to cause recurrence. For most of the peptides people ask about, nobody has studied women with a cancer history at all. What we have is biology, which tells you which peptides deserve the most caution.

The clearest concern is the growth hormone (GH) / IGF-1 axis. Large studies link higher blood IGF-1 to a modestly higher risk of oestrogen-receptor-positive (ER+) breast cancer. GH secretagogues such as sermorelin, CJC-1295, ipamorelin, MK-677 and tesamorelin exist to raise GH and IGF-1. That is why they are a question for your oncologist, not a wellness clinic.

GLP-1 drugs (semaglutide, tirzepatide) are the best-studied group. Randomised trials show no clear change in breast cancer risk, and early observational data in survivors look reassuring. Prospective trials in breast cancer patients are running now. Topical cosmetic peptides have no known hormonal mechanism.

The key points:

• Higher IGF-1 is linked to ER+ breast cancer risk in pooled prospective data and UK Biobank, and genetic studies point the same way.
• GH secretagogues raise IGF-1 by design. The FDA label for tesamorelin lists active malignancy as a contraindication.
• BPC-157 and TB-500 promote blood-vessel growth in animal and lab studies. This is a theoretical concern with no human data either way.
• GLP-1 trials show no clear breast cancer signal. The thyroid boxed warning is about a different tumour type.
• Kisspeptin switches on the reproductive hormone axis, which matters in hormone-sensitive disease.
• Every decision belongs with your oncology team, ideally before you start anything.

Why does the IGF-1 axis matter after breast cancer?

Evidence tier: 3 — large prospective pooled analysis, UK Biobank cohort and Mendelian randomisation; associations, not trials.

IGF-1 is a growth signal made mostly in the liver in response to growth hormone. It tells cells to grow and divide and helps them survive. Breast tissue responds to it.

Two large analyses are the backbone of the concern:

• Pooled analysis, 2010. The Endogenous Hormones and Breast Cancer Collaborative Group combined 17 prospective studies (4,790 cases, 9,428 controls). Women in the highest fifth of IGF-1 had 28% higher odds of breast cancer than those in the lowest fifth. The link was seen for ER+ tumours (OR 1.38) but not ER-negative ones (PMID 20472501).
• UK Biobank, 2020. Among 206,263 women, each 5 nmol/L rise in IGF-1 was linked to an 11% higher risk of breast cancer. A genetic (Mendelian randomisation) analysis found a smaller but consistent effect for ER+ tumours, which suggests the link may be partly causal (PMID 32169310).

Some limits are worth keeping in mind. These studies looked at whether women developed a first breast cancer, not at recurrence. The effect sizes are modest. And natural IGF-1 levels are not the same thing as levels pushed up by a drug. Still, the direction is consistent, and it is strongest for the hormone-sensitive tumours that make up most breast cancers.

Are GH-releasing peptides safe after breast cancer?

Evidence tier: 1 for the tesamorelin label; 2–4 for the IGF-1 effects of the others; no outcome data in survivors.

These peptides raise GH and, as a result, IGF-1. That is their purpose:

The tesamorelin (Egrifta WR) label is the clearest regulatory statement. It is contraindicated in active malignancy. It tells prescribers to weigh the background risk of cancer before starting and to stop if there is any sign of recurrent malignancy. It also notes that the effects of long-term raised IGF-1 are unknown (FDA label via Drugs.com). The unapproved secretagogues have no label at all, so none of this checking is built in.

No study has tested any of these peptides in breast cancer survivors. So nobody can give you a risk figure. Together with the IGF-1 data, though, this is why they are a decision for the cancer team. If you are offered one, bring it to that team first.

What about BPC-157 and TB-500?

Evidence tier: 4 — cell and animal studies only; no human cancer data in either direction.

Both are sold for "healing", and both act partly by growing new blood vessels (angiogenesis). Tumours also depend on new blood vessels.

• BPC-157 turned on the VEGFR2 pathway and increased new vessel growth in rat and cell studies (PMID 27847966). A 2026 systematic review found only three small human studies (30 people) of any kind. All were of poor quality, and none involved people with cancer (PMID 42885452).
• TB-500 is a fragment-based product modelled on thymosin beta-4. In human breast tumour samples, high thymosin beta-4 levels went along with lymph-node spread and VEGF signalling (PMID 21109953). That is a correlation inside tumours, not evidence that injecting TB-500 causes cancer.

The honest summary: a plausible mechanism for harm, no human data to confirm or rule it out. Neither peptide is an approved medicine in the US, EU or UK. In April 2026 the FDA took BPC-157 and TB-500 off its Category 2 list after the nominations were withdrawn. That did not make them legal to compound (National Law Review). Quality from grey-market sellers is unknown. The same "growth signal" logic is covered for dihexa in our dihexa and cancer risk article.

Are GLP-1 drugs safe with a breast cancer history?

Evidence tier: 2 for cancer incidence (RCT meta-analysis); 3 for outcomes in survivors (retrospective cohorts).

This is the group with the most data, and so far it does not point to harm.

• Trials in the general population. A 2026 meta-analysis of 48 placebo-controlled trials (94,245 people) found GLP-1 drugs probably have little or no effect on breast cancer risk (OR 0.95, moderate certainty) (PMID 41359966).
• Women who already had breast cancer. Two large US database studies from 2026 linked GLP-1 use to lower death and recurrence rates in survivors with obesity or diabetes (PMID 42113513; PMID 42813380). Both studies were retrospective. Healthier or better-insured women may be more likely to get a GLP-1, and the authors call for prospective or randomised trials. They do not show that GLP-1s prevent recurrence.
• Weight on hormone therapy. Cancer treatment, including endocrine therapy, often leads to weight gain and insulin resistance (PMID 42385128). In one 2026 cohort of women taking endocrine therapy with a GLP-1, average weight loss after a year was 4.5%, well below what the obesity trials reported (PMID 42932003).
• Trials under way. Prospective trials are now enrolling women with early hormone-receptor-positive breast cancer, for example a phase 2 tirzepatide trial in HR+/HER2− disease (NCT06518837).

The thyroid boxed warning on semaglutide and tirzepatide is about medullary thyroid carcinoma seen in rodents. The drugs are contraindicated if you or a family member have had MTC or MEN 2 (Wegovy label). It is not a breast cancer warning. Our GLP-1 cancer headlines explained article covers it in detail. Rapid weight loss can change how mammograms look, including breast density (PMID 42385128), so tell the breast imaging team if you are on a GLP-1.

Is kisspeptin a concern in hormone-sensitive cancer?

Evidence tier: 4 — human physiology studies of the reproductive axis; cancer data are laboratory only.

Kisspeptin sits at the top of the reproductive hormone chain. It triggers GnRH release, which drives LH and FSH, which in turn drive the ovaries to make oestrogen (PMID 24615662). In a premenopausal woman, that means kisspeptin can push oestrogen production up.

That runs against the goal of many treatments for ER+ breast cancer, which aim to switch ovarian oestrogen off. Goserelin, for example, is licensed in the UK for ER+ breast cancer in premenopausal women for exactly this reason (Zoladex SmPC).

Laboratory work on the kisspeptin receptor in breast cancer is mixed. Some studies suggest it helps triple-negative tumours grow and spread (PMID 32034133). Kisspeptin is not an approved medicine anywhere and is used only in research settings.

Are topical peptides like GHK-Cu and Argireline a concern?

Evidence tier: 4 — mechanistic reviews and small cosmetic studies; no studies in cancer survivors.

Skin-care peptides work locally. GHK-Cu (copper peptide) affects collagen and wound-repair genes in skin (PMID 26236730). Argireline (acetyl hexapeptide-8) is used for expression lines. One 2026 clinical study tested it as part of a multi-ingredient serum (PMID 41668671).

Neither has a known action on oestrogen, progesterone or the GH axis. How much reaches the bloodstream from a cream has not been well measured, but it is expected to be small. Injected GHK-Cu is a different matter. It gives far higher exposure, has not been studied for safety in people, and is also caught up in the US compounding review. Radiation-treated skin and skin near reconstruction sites can react differently, so check with your breast care nurse before using new actives there.

What should I ask my oncology team?

Evidence tier: 4 — editorial synthesis of the evidence above.

Take the product name, dose and source with you. Useful questions:

1. Was my tumour ER-positive, PR-positive or HER2-positive, and does that change how you view this peptide?
2. Does this peptide raise IGF-1, oestrogen or LH/FSH, and do you want those measured before and during use?
3. Could it interact with my tamoxifen, aromatase inhibitor, ovarian suppression or other targeted therapy?
4. If weight gain on endocrine therapy is the goal, is a prescribed GLP-1 an option, or is there a trial I could join?
5. Would recurrence surveillance pick up anything this product might affect?
6. If it is a grey-market product, what risks come from contamination or wrong dosing?

Our labs before and during peptides guide explains IGF-1 and hormone testing in plain terms.

Limitations of the evidence

Evidence tier: — summary of the evidence gaps above.

• No peptide has been studied for safety in breast cancer survivors.
• The IGF-1 data are observational and genetic, cover first cancers rather than recurrence, and natural IGF-1 levels differ from drug-raised ones.
• Cancer data for BPC-157, TB-500 and kisspeptin come only from animal, cell or tumour-tissue studies.
• The GLP-1 survivor studies are retrospective database analyses open to healthy-user bias. Prospective trials are still enrolling.
• How much of a topical peptide reaches the bloodstream hasn't been well measured.

The bottom line

The risk is not the same across peptides. GH secretagogues and kisspeptin act on hormone systems that matter in breast cancer. BPC-157 and TB-500 raise a plausible but unproven concern and have no human safety data. GLP-1 drugs have the most reassuring evidence so far, and proper trials in survivors are under way. Topical cosmetic peptides are the lowest-concern group. In every case, your oncologist knows your tumour biology and your treatment, so the decision belongs with them.

Related on this site

• GLP-1 cancer headlines explained
• Dihexa and cancer risk: the HGF/c-Met question
• BPC-157: animal vs human evidence
• Labs before and during peptides
• Kisspeptin and female sexual health
• Age-related GH decline: what interventions do
• Peptides in perimenopause and menopause

References

• Endogenous Hormones and Breast Cancer Collaborative Group. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010 — IGF-1 link confined to ER+ tumours. PMID 20472501
• Murphy N et al. Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ∼430 000 women. Ann Oncol 2020 — UK Biobank plus genetic analysis. PMID 32169310
• Theratechnologies. EGRIFTA WR (tesamorelin) prescribing information. 2025 — malignancy and IGF-1 warnings. Drugs.com
• Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab 2006 — IGF-1 raised for days. PMID 16352683
• Nass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med 2008 — MK-677 12-month RCT. PMID 18981485
• Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998 — animal pharmacology. PMID 9849822
• Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med 2017 — angiogenesis in rats and cells. PMID 27847966
• Poolton JT et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review. Acta Orthop Belg 2026 — three poor-quality human studies. PMID 42885452
• Yoon SY et al. Thymosin β4 expression correlates with lymph node metastasis through HIF-α induction in breast cancer. Oncol Rep 2011 — tumour tissue correlation. PMID 21109953
• Ko A et al. Risk for cancer with GLP-1 receptor agonists and dual agonists: a systematic review and meta-analysis. Ann Intern Med 2026 — 48 RCTs, no breast cancer signal. PMID 41359966
• Tatum KL et al. Survival and recurrence with GLP-1 receptor agonists in breast cancer. JAMA Netw Open 2026 — retrospective TriNetX cohort. PMID 42113513
• Den J et al. The effect of GLP-1 receptor agonists on peri- and postmenopausal breast cancer outcomes. J Surg Oncol 2026 — retrospective, BMI ≥35. PMID 42813380
• Hundal J et al. GLP-1 receptor agonists in breast cancer: metabolic, clinical, and survivorship implications. JCO Oncol Pract 2026 — clinical review. PMID 42385128
• Cronin KM et al. GLP-1 receptor agonist-associated weight loss in breast cancer patients receiving concurrent endocrine therapy. Breast Cancer Res Treat 2026 — attenuated weight loss. PMID 42932003
• Novo Nordisk. WEGOVY (semaglutide) prescribing information. 2024 — thyroid C-cell boxed warning. FDA label
• Skorupskaite K et al. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update 2014 — reproductive axis physiology. PMID 24615662
• Dragan M et al. G protein-coupled kisspeptin receptor induces metabolic reprograming and tumorigenesis in ER-negative breast cancer. Cell Death Dis 2020 — laboratory and mouse data. PMID 32034133
• Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015 — mechanistic review. PMID 26236730
• Zhu M et al. The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture. Int J Cosmet Sci 2026 — combination product study. PMID 41668671
• AstraZeneca. Zoladex 3.6 mg implant SmPC. — ER+ breast cancer and endometriosis indications. EMC
• National Law Review. Tiny chains, big changes: what FDA's latest actions mean for peptide compounding. 2026 — Category 2 removal context. Link